Small Cap Update

Belgian Galapagos and AbbVie will boost their joint venture in developing a triple drug combo to treat cystic fibrosis. The milestones to the Belgian company were upped for phase 1 and 2 goals from $350 mn to $600 mn.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.